Sequana Therapeutics Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$166M
Sequana Therapeutics General Information
Description
Operator of a therapeutics company intended to develop proprietary gene therapy products. The company's products are developed using a gene discovery technology, enabling medical researchers to facilitate relatively rapid isolation and characterization of disease genes.
Contact Information
Corporate Office
- 11099 North Torrey Pines Road
- Suite 160
- San Diego, CA 92037
- United States
Corporate Office
- 11099 North Torrey Pines Road
- Suite 160
- San Diego, CA 92037
- United States
Sequana Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 09-Jan-1998 | $166M | Completed | Clinical Trials - General | ||
| 1. Early Stage VC | Completed | Clinical Trials - General |
Sequana Therapeutics Patents
Sequana Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-6100058-A | Nucleic acid encoding a mammalian protein having specific amino acid sequence and involved in abnormal growth control; anticarcinogenic agents; for identifying homologous or related genes; gene therapy; mapping of protein regions | Inactive | 12-Aug-1997 | ||
| US-5705380-A | Identification of a gene encoding tulp2, a retina specific protein | Inactive | 04-Sep-1996 | ||
| US-5686598-A | Genes associated with retinal dystrophies | Inactive | 22-Aug-1996 | ||
| WO-1997038004-A1 | Gene family associated with neurosensory defects | Inactive | 10-Apr-1996 | ||
| US-5776762-A | Isolated cells and nucleic acids | Inactive | 10-Apr-1996 | C07K14/47 |
Sequana Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avalon Ventures | Venture Capital | Minority | ||
| Morgenthaler | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| New Leaf Venture | Venture Capital | Minority | ||
| Roche Venture Fund | Corporate Venture Capital | Minority |
Sequana Therapeutics Investments (1)
Sequana Therapeutics’s most recent deal was a Later Stage VC with Aurora Biosciences for . The deal was made on 02-May-1996.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aurora Biosciences | 02-May-1996 | Later Stage VC | Drug Discovery |
Sequana Therapeutics FAQs
-
When was Sequana Therapeutics founded?
Sequana Therapeutics was founded in 1993.
-
Where is Sequana Therapeutics headquartered?
Sequana Therapeutics is headquartered in San Diego, CA.
-
What industry is Sequana Therapeutics in?
Sequana Therapeutics’s primary industry is Biotechnology.
-
Is Sequana Therapeutics a private or public company?
Sequana Therapeutics is a Private company.
-
What is the current valuation of Sequana Therapeutics?
The current valuation of Sequana Therapeutics is .
-
What is Sequana Therapeutics’s current revenue?
The current revenue for Sequana Therapeutics is .
-
Who are Sequana Therapeutics’s investors?
Avalon Ventures, Morgenthaler, New Enterprise Associates, New Leaf Venture, and Roche Venture Fund are 5 of 6 investors who have invested in Sequana Therapeutics.
-
When was Sequana Therapeutics acquired?
Sequana Therapeutics was acquired on 09-Jan-1998.
-
Who acquired Sequana Therapeutics?
Sequana Therapeutics was acquired by AXYS Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process